Filter posts

New BIO Report on State of Innovation for Alzheimer’s Disease Therapeutics

Today, BIO released a new report: The State of Innovation in Highly Prevalent Chronic Diseases …

“Health Care’s Big Spending Mismatch”

This week, Axios reported on new data that shows “the health care services that rack …

Promising Results Offer Hope in Fight Against Candida auris

While health care conversations on Capitol Hill today are largely focused on how to best …

WSJ: Drug Importation is “Impractical, Unsafe and Unlikely” to Lower Prices

This week, Editorial Board writers for The Wall Street Journal examined a policy proposal in …

Greenwood: In Pharma Value Chain, PBMs Manage to Benefit

Writing for The Hill, BIO’s President and CEO Jim Greenwood offered praise to the Senate Finance …

Oncologist Warns of IPI’s Potentially Dangerous Implications

Writing for Morning Consult, Dr. Lucy Langer, a clinical oncologist with Compass Oncology in Portland, …

Peter Pitts Examines the Role of PBMs and their Deceptive Tactics

A piece by Peter J. Pitts, a former FDA Associate Commissioner and President of the …

Vaccines Work: the Proof Is in the Data.

At the latest meeting of the Advisory Committee on Immunization Practices (ACIP), more than 80 …

Kentucky Officials Expose PBMs for Gaming the System

While many were watching the drug pricing debate unfold on Capitol Hill, the Kentucky Cabinet …

Two New Infographics Illustrate the Success of the Orphan Drug Act

In recognition of Rare Disease Day, BIO’s Jim Greenwood shared commentary on LinkedIn celebrating the …